Development
Biodesix, Inc.
BDSX
$0.3029
$0.02117.49%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 14.67M | 13.49M | 11.87M | 9.06M | 9.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.67M | 13.49M | 11.87M | 9.06M | 9.61M |
| Cost of Revenue | 3.37M | 3.23M | 3.24M | 3.17M | 3.31M |
| Gross Profit | 11.29M | 10.26M | 8.63M | 5.89M | 6.30M |
| SG&A Expenses | 16.25M | 15.50M | 16.65M | 18.99M | 16.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.51M | 20.66M | 22.80M | 25.41M | 23.50M |
| Operating Income | -6.85M | -7.17M | -10.93M | -16.35M | -13.89M |
| Income Before Tax | -9.14M | -10.95M | -13.36M | -18.70M | -20.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.14M | -10.95M | -13.36M | -18.70M | -20.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.14M | -10.95M | -13.36M | -18.70M | -20.34M |
| EBIT | -6.85M | -7.17M | -10.93M | -16.35M | -13.89M |
| EBITDA | -5.87M | -6.39M | -10.14M | -15.57M | -12.99M |
| EPS Basic | -0.10 | -0.14 | -0.17 | -0.24 | -0.35 |
| Normalized Basic EPS | -0.06 | -0.09 | -0.11 | -0.15 | -0.18 |
| EPS Diluted | -0.10 | -0.14 | -0.17 | -0.24 | -0.35 |
| Normalized Diluted EPS | -0.06 | -0.09 | -0.11 | -0.15 | -0.18 |
| Average Basic Shares Outstanding | 92.33M | 79.71M | 78.51M | 77.77M | 57.81M |
| Average Diluted Shares Outstanding | 92.33M | 79.71M | 78.51M | 77.77M | 57.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |